Author:
Dredge K,Marriott J B,Macdonald C D,Man H-W,Chen R,Muller G W,Stirling D,Dalgleish A G
Publisher
Springer Science and Business Media LLC
Reference36 articles.
1. Bauer KS, Dixon SC, Figg WD (1998) Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. Biochem Pharmacol 55: 1827–1834
2. Bishop ET, Bell GT, Bloor S, Broom IJ, Hendry NFK, Wheatly DN (2000) An in vitro model of angiogenesis: Basic features. Angiogenesis 3(4): 335–344
3. Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407: 249–257
4. Corral LG, Haslett PA, Muller GW, Chen R, Wong LM, Ocampo CJ, Patterson RT, Stirling DI, Kaplan G (1999) Differential cytokine modulation and T cell activation by two distinct classes of Thd analogues that are potent inhibitors of TNF-α. J Immunol 163: 380–386
5. D'Amato JD, Loughnan MS, Flynn E, Folkman J (1994) Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci 91: 4082–4085
Cited by
273 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献